Group items matching

in title, tags, annotations or url

This Funding Opportunity Announcement (FOA) invites research project applications to conduct ancillary studies to major ongoing clinical research studies, including clinical trials and prospective observational studies. Applications submitted to this FOA must propose to collect new information and/or biological samples directly from participants of the ongoing parent study, and must address new research questions that are beyond those specified in the approved protocol of the parent study and are within the scientific mission of the NIDDK.

DARPA seeks innovative proposals to develop technology for enhancing cognitive skill learning in healthy adults by using noninvasive peripheral neurostimulation to promote synaptic plasticity in the brain. The Targeted Neuroplasticity Training (TNT) program will elucidate the anatomical and functional map of the underlying neural circuity involved in regulating synaptic plasticity. The program seeks to demonstrate peripheral modulation of the neural circuit, connect neuroplasticity with cognitive improvements, and optimize intervention protocols for long term retention with no side effects.

This FOA invites applications for a Biostatistics Research Center to participate in a clinical consortium to carefully characterize the course of glycemia over the entire duration of pregnancy and understand the evolution of dysglycemia when it occurs. A separate FOA (RFA-DK-18-018) invites Clinical Centers to recruit and study pregnant women starting in the first trimester, and continuing at least through delivery. All awardees will form a cooperative research consortium in conjunction with NIDDK to design and implement a uniform protocol. Information obtained from this study is expected to lead to improved approaches for screening for GDM, and inform the timing and approach for future clinical trials to decrease adverse perinatal outcomes and long-term sequelae of dysglycemia during pregnancy in both the mother and offspring.

This FOA invites applications for Clinical Centers to carefully characterize the normal course of glycemia over the entire duration of pregnancy and understand the evolution of dysglycemia when it occurs. Clinical Centers will recruit and study pregnant women starting in the first trimester and continuing at least through delivery. A separate FOA (RFA-DK-18-019) will solicit a Biostatistics Research Center. Each Clinical Center applicant will propose a study design and provide detailed information about recruitment capacity. All awardees will form a cooperative research consortium in conjunction with NIDDK to design and implement a uniform protocol. Information obtained from this study is expected to lead to improved approaches for screening for GDM, and inform the timing and approach for future clinical trials to decrease adverse perinatal outcomes and long-term sequelae of dysglycemia during pregnancy in both the mother and offspring.

The purpose of the Field Initiated (FI) Projects program is to develop methods, procedures, and rehabilitation technology that maximize the full inclusion and integration into society, employment, independent living, family support, and economic and social self-sufficiency of individuals with disabilities, especially individuals with the most severe disabilities. Another purpose of the FI Projects program is to improve the effectiveness of services authorized under the Rehabilitation Act of 1973, as amended. The purpose of this MSI-FI competition is to improve the capacity of minority entities to engage in disability and rehabilitation research and development activities. NIDILRR will accomplish this by limiting eligibility for this completion to minority entities and Indian tribes in a manner consistent with Sections 21(b)(2)(A) of the Act, which authorizes NIDILRR to make awards to minority entities and Indian tribes to carry out activities authorized under Title II of the Act. NIDILRR is particularly interested in applications from individual minority entities that have historically been underrepresented in the Federally-sponsored research arena. In carrying out a development activity under a FI Projects development grant, a grantee must use knowledge and understanding gained from research to create materials, devices, systems, methods, measures, techniques, tools, protypes, processes, or intervention protocols that are beneficial to the target population. Please note that this will be the funding opportunity for FI development proposals for minority-serving institutions.

The purpose of this FOA is to identify and support a Data Integration and Resource Center (DIRC) for the Common Fund Acute to Chronic Pain Signatures (A2CPS) Program. The overall programmatic goal of the DIRC is to integrate the efforts of all funded components of the A2CPS and serve as a community-wide nexus for protocols, data, assay and data standards, and other resources generated by the A2CPS Program.

Invasive surgical procedures provide the unique ability to record and stimulate neurons within precisely localized brain structures in humans. Human studies using invasive technology are often constrained by a limited number of patients and resources available to implement complex experimental protocols and are rarely aggregated in a manner that addresses research questions with appropriate statistical power. Therefore, this RFA seeks applications to assemble diverse, integrated, multi-disciplinary teams that cross boundaries of interdisciplinary collaboration to overcome these fundamental barriers and to investigate high-impact questions in human neuroscience. Projects should maximize opportunities to conduct innovative in vivo neuroscience research made available by direct access to brain recording and stimulating from invasive surgical procedures.

Invasive surgical procedures provide the unique ability to record and stimulate neurons within precisely localized brain structures in humans. Human studies using invasive technology are often constrained by a limited number of patients and resources available to implement complex experimental protocols and are rarely aggregated in a manner that addresses research questions with appropriate statistical power. Therefore, this RFA seeks applications to assemble diverse, integrated, multi-disciplinary teams that cross boundaries of interdisciplinary collaboration to overcome these fundamental barriers and to investigate high-impact questions in human neuroscience. Projects should maximize opportunities to conduct innovative in vivo neuroscience research made available by direct access to brain recording and stimulating from invasive surgical procedures. Projects should employ approaches guided by specified theoretical constructs and quantitative, mechanistic models where appropriate. Awardees will join a consortium work group, coordinated by the NIH, to identify consensus standards of practice, including neuroethical considerations, to collect and provide data for ancillary studies, and to aggregate and standardize data for dissemination among the wider scientific community.

The purpose of this Funding Opportunity Announcement is to foster the advancement of the research mission of the Division of Digestive Diseases and Nutrition, NIDDK by soliciting research concepts that for pilot and feasibility clinical study proposals would need further assessment of identified protocol operational challenges would enhance operational feasibility of achieving successful completion of a subsequent larger clinical study; or for clinical translational science proposals, promote exploratory and novel science through the use of human subjects. The following studies will not be supported by this FOA: those that have obesity as a component of the study proposal (please refer to the Office of Extramural Research Grants and Funding to search for multiple obesity related Funding Opportunity Announcements at https://grants.nih.gov/grants/oer.htm); and translational studies that utilize animal models.

This U01 Cooperative Agreement Funding Opportunity Announcement (FOA) will support 3-4 U01 Methods Comparison Projects to serve three main functions: (1) to conduct a joint effort among telomere researchers to determine the relationship between different telomere length (TL) methods, inter-assay variability, and the factors that influence results; (2) Contribute to development of best practice recommendations for assay protocols for TL measurement for different types of studies, with a focus on population-based health research, including biological sample collection, storage, and processing; laboratory methods; data analysis; and reporting requirements; and (3) Repurpose existing methods or develop new methods to enhance the use of TL measurement.

This Funding Opportunity Announcement invites applications for a U24 Telomere Research Network/Collaboratory. This U24 will coordinate activities of a telomere length (TL) methods comparison study involving multiple labs supported under U01 awards made in response to FOA (RFA-AG-19-023) to address the need for cross-validation between protocols and samples for establishing best practices for population-based TL research. The U24 will serve as the central resource for the organization of meetings and other activities of this coordinated program, including support for the methods study, dissemination of its results and resultant recommendations. It will also develop and foster an extended Telomere Research Network (TRN) connecting the broader field through a flexible range of activities that will advance an interdisciplinary research agenda on telomeres and activities directly associated with TL maintenance as sentinels of environmental exposures, psychosocial stress, and disease susceptibility.

This Funding Opportunity Announcement invites applications for a U24 Telomere Research Network/Collaboratory. This U24 will coordinate activities of a telomere length (TL) methods comparison study involving multiple labs supported under U01 awards made in response to FOA (RFA-AG-19-023) to address the need for cross-validation between protocols and samples for establishing best practices for population-based TL research. The U24 will serve as the central resource for the organization of meetings and other activities of this coordinated program, including support for the methods study, dissemination of its results, and resultant recommendations. It will also develop and foster an extended Telomere Research Network (TRN) connecting the broader field through a flexible range of activities that will advance an interdisciplinary research agenda on telomeres and activities directly associated with TL maintenance as sentinels of environmental exposures, psychosocial stress, and disease susceptibility. 

This U01 Cooperative Agreement Funding Opportunity Announcement (FOA) will support Methods Comparison Projects to serve three main functions: (1) to conduct a joint effort among telomere researchers to determine the relationship between different telomere length (TL) methods, inter-assay variability, and the factors that influence results; (2) to contribute to development of best practice recommendations for assay protocols for TL measurement for different types of studies, with a focus on population-based health research, including biological sample collection, storage, and processing; laboratory methods; data analysis; and reporting requirements; and (3) to repurpose existing methods or develop new methods to enhance the use of TL measurement.

This Funding Opportunity Announcement (FOA) solicits applications to develop standards that describe experimental protocols that are being conducted as part of the BRAIN Initiative.It is expected that applications will solicit community input at all stages of the process. It is recommended that the first step of standard development will involve sharing data between different key groups in the experimental community in order to ensure that the developing standard will cover the way that all of those groups are collecting data. The developed standard is expected to be made widely available.

 The purpose of this Funding Opportunity Announcement (FOA) is to support Large Animal Testing Centers to evaluate in vivo genome editing technologies developed by other investigators in the Somatic Cell Genome Editing Program (SCGE). Each Testing Center will use wild-type pigs or non-human primates, as well as reporter animals developed under RFA-RM-18-013. The Testing Centers will work collaboratively with investigators funded under RFA-RM-18-016 and RFA-RM-18-017 to assess efficacy and safety of in vivo genome editing and delivery technologies. Testing Centers will breed, archive and maintain cohorts of well characterized and genotyped large animals, establish methods and protocols for the evaluation of the delivery systems and editing tools, conduct testing and provide results to the SCGE Dissemination and Coordination Center. Such activities will accelerate the translation of genome editing technologies into treatments for human diseases.  

The purpose of this FOA is to establish a center to coordinate and analyze single cell and other molecular data sets generated by SCORCH and other NIDA-funded HIV and substance use disorder projects and to make the data findable, accessible, interoperable, and reusable (FAIR) to enable secondary analyses by the scientific community. The SCORCH Data Center will coordinate, curate, analyze, and provide public access to single cell SCORCH datasets and other NIDA-generated molecular HIV/SUD data. The SCORCH Data Center will also be responsible for integrating the efforts of all funded components of the NIDA SCORCH program and serve as a community-wide nexus for single cell protocols, data, assay and data standards, and other resources generated by the program. The SCORCH Data Center and NIH staff will need to work closely together to accomplish these goals. Applications that are not responsive to this FOA will not be reviewed.  To be responsive to this FOA, projects should be framed to answer one or more vexing questions about persistent HIV infection in the brain.  In addition, the major thrust of the proposed project MUST: propose to coordinate and analyze single cell and other molecular data sets generated by SCORCH and other NIDA-funded HIV and substance use disorder projects. propose to make this data findable, accessible, interoperable, and reusable (FAIR) to enable secondary analyses by the scientific community.

NCATS plans to support the research, development and testing of up to three biomedical reasoning tool prototypes for the Biomedical Data Translator for an estimated $1,000,000 total costs each. NCATS is utilizing a three-step application process (challenge-concept-proposal) for this expedited program. The duration of each award will be less than one year. All awardees will be expected to collaborate and cooperate with NCATS staff, one another and potentially other contributors to the overall program to maximize the exploration of the potential capabilities of Translator and to understand technical feasibility and challenges of having multiple groups build a single resource. All U.S. and foreign organizations and U.S. citizens are eligible to apply. This funding opportunity is open to U.S. and foreign organizations, including academic institutions and commercial entities; subcontracts are allowed. U.S. citizens may also apply as individuals and may be direct recipients of an award. Non-citizen individuals residing in the U.S. or foreign country not affiliated with either a U.S. or foreign organization are not eligible to be direct recipients of an award. Successful completion of the application process will require applicants to have specific skills related to translational research and software development. Applicants need to demonstrate technical skills, including familiarity with web communication protocols, a variety of programming languages and software stack, and general algorithmic techniques in the areas of artificial intelligence, machine learning, and knowledge engineering, as well as problem solving skills, especially creativity and persistence. Applicants familiar with languages and packages most useful for solving different tasks, the entire challenge process may take between 2 and 8 hours to complete.

The Chronic Kidney Disease Biomarkers Consortium [CKD BioCon] was established in September 2009 as a result of RFA-DK-08-015 [Chronic Kidney Disease Biomarker Discovery and Validation Consortium (U01)] to develop, validate and qualify biomarkers based on existing biosamples from well-characterized CKD patients with longitudinal follow-up. The second phase of the CKD BioCon was funded in September 2014, pursuant to RFA-DK-14-011.  Two additional Centers were brought into the Consortium in 2015.  The CKD BioCon currently consists of eight Participating Clinical Centers (PCCs) and is actively engaged in multiple research protocols.

The purpose of this initiative is to support Genomic Centers for Infectious Diseases (GCID) to promote broad use and expand the application of genomics technologies and computational analysis to understand infectious diseases, with an emphasis on pathogens, their interaction with the host and microbiome, and to aid in the development of novel genomics-based tools to diagnose, prevent and treat infectious diseases. The GCID will support innovative technology development in all aspects of genomics, including the use of synthetic and genome editing technologies as well as functional genomics to address basic, translational, and clinically relevant questions in host-pathogen interactions. The knowledge generated, including research data, analytical software tools, computational models, experimental protocols, and reagents, is expected to be widely disseminated to the scientific community through publicly accessible databases and reagent repositories.

The NICHD invites applications from investigators to develop a multi-site project designed to conduct clinical trials to investigate problems in reproductive medicine, female and male infertility, and gynecologic and male reproductive system diseases and disorders that impact fertility. This funding opportunity announcement (FOA) is intended to support multi-site clinical research consortia devoted to evaluating safety and efficacy of new medications, treatments and technologies addressing questions in infertility.  The objective of this program is to advance scientific research that facilitates diagnostic and therapeutic solutions to infertility by using common protocols in large scale human trials to obtain answers more rapidly than individual sites acting alone.